WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Gregory H. Bailey net worth and biography

Gregory Bailey Biography and Net Worth

Director of Biohaven

Dr. Bailey has spent the last fifteen years as an entrepreneur, executive and financier in the health care sector. He is currently Chairman of the Board at Portage Biotech Inc. and has served on the Board of Directors for 16 public companies. He is a former director and financier of Medivation Inc. (MDVN: NASDAQ) and co-founder of Ascent Healthcare Solutions, VirnetX Inc internet security (VHC: AMEX) and Duramedic Inc., a medical products company. Prior posts within the investment and financial services sector included serving as Managing Director of Gilford Securities Inc., Managing Director of Knightsford Bank Corp, Senior Managing Director positions at Viscogliosi Brothers and the LXV Prosperity Fund, founder and General Manager of the ABN Private Equity Fund, co-foundeer of EuroAmerican Mercantile Bancorp, and co-founder and CEO of V-Fund Investments, Ltd. Dr. Bailey received his Medical Degree from the University of Western Ontario before practicing for ten years as an emergency room Physician.

What is Gregory H. Bailey's net worth?: The estimated net worth of Gregory H. Bailey is at least $58.74 million as of September 24th, 2024. Dr. Bailey owns 1,620,071 shares of Biohaven stock worth more than $58,743,774 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Bailey may own. Learn More about Gregory H. Bailey's net worth.
How do I contact Gregory H. Bailey?: The corporate mailing address for Dr. Bailey and other Biohaven executives is 215 CHURCH STREET, NEW HAVEN CT, 06510. Biohaven can also be reached via phone at 203-404-0410 and via email at [email protected]. Learn More on Gregory H. Bailey's contact information.
Has Gregory H. Bailey been buying or selling shares of Biohaven?: Gregory H. Bailey has not been actively trading shares of Biohaven during the last ninety days. Most recently, on Tuesday, September 24th, Gregory Bailey bought 5,000 shares of Biohaven stock. The stock was acquired at an average cost of $44.19 per share, with a total value of $220,950.00. Following the completion of the transaction, the director now directly owns 1,620,071 shares of the company's stock, valued at $71,590,937.49. Learn More on Gregory H. Bailey's trading history.
Who are Biohaven's active insiders?: Biohaven's insider roster includes Irina Antonijevic (Director), Gregory Bailey (Director), Robert Berman (Insider), Matthew Buten (CFO), John Childs (Director), George Clark (CAO), Vlad Coric (CEO), Declan Doogan (Director), James Engelhart (CFO), Kimberly Gentile (SVP), Julia Gregory (Director), William Jones, Jr. (Insider), Elyse Stock (Insider), and John Tilton (Insider). Learn More on Biohaven's active insiders.
Are insiders buying or selling shares of Biohaven?: In the last twelve months, Biohaven insiders bought shares 8 times. They purchased a total of 307,186 shares worth more than $12,231,711.54. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 11,000 shares worth more than $459,690.00. The most recent insider tranaction occured on October, 2nd when Director John W Childs bought 21,052 shares worth more than $999,970.00. Insiders at Biohaven own 16.0% of the company. Learn More about insider trades at Biohaven.
Information on this page was last updated on 10/2/2024.

Gregory H. Bailey Insider Trading History at Biohaven

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/24/2024	Buy	5,000	$44.19	$220,950.00	1,620,071
4/24/2024	Buy	25,503	$39.18	$999,207.54	1,600,071
4/22/2024	Buy	48,780	$41.00	$1,999,980.00	1,574,568
10/4/2023	Buy	17,817	$22.57	$402,129.69	1,525,788
10/25/2022	Buy	200,000	$10.50	$2,100,000.00	1,507,971
8/19/2022	Buy	38,000	$148.04	$5,625,520.00	2,583,658
10/22/2020	Sell	24,566	$79.47	$1,952,260.02	2,559,161
10/19/2020	Sell	4,554	$78.98	$359,674.92	2,585,181
10/16/2020	Sell	3,748	$78.88	$295,642.24	2,585,181
10/12/2020	Sell	6,729	$78.87	$530,716.23	2,588,929
7/8/2020	Sell	50,000	$75.22	$3,761,000.00	2,601,649
6/24/2020	Sell	3,995	$69.86	$279,090.70	2,737,829
6/22/2020	Sell	80,331	$73.24	$5,883,442.44	2,973,646
6/19/2020	Sell	164,031	$71.22	$11,682,287.82	2,973,646
8/20/2019	Buy	5,000	$37.65	$188,250.00	2,587,601
1/31/2018	Sell	50,000	$33.71	$1,685,500.00	2,516,701
1/22/2018	Sell	49,000	$30.76	$1,507,240.00	2,583,289
1/16/2018	Sell	40,000	$26.52	$1,060,800.00
1/4/2018	Sell	50,000	$28.71	$1,435,500.00	1,187,275
12/20/2017	Sell	39,430	$26.31	$1,037,403.30	1,234,077
11/30/2017	Sell	9,970	$25.48	$254,035.60	1,262,759
11/27/2017	Sell	20,600	$25.92	$533,952.00	1,289,699
11/24/2017	Sell	600	$26.02	$15,612.00	1,289,699

Gregory H. Bailey Buying and Selling Activity at Biohaven

Biohaven Company Overview

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $36.26

$34.46

$36.95

50 Day Range

MA: $47.21

$35.34

$53.69

2 Week Range

Now: $36.26

$26.80

$62.21

Volume

3,229,003 shs

Average Volume

1,130,245 shs

Market Capitalization

$3.67 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24